Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation

Estrogen receptor alpha (ERα)-positive breast cancers are frequently treated with tamoxifen, but resistance is common. It remains elusive how tamoxifen resistance occurs and predictive biomarkers for treatment outcome are needed. Because most biomarker discovery studies are performed using pre-treat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Severson, Tesa M., Nevedomskaya, Ekaterina, Peeters, Justine, Kuilman, Thomas, Krijgsman, Oscar, van Rossum, Annelot, Droog, Marjolein, Kim, Yongsoo, Koornstra, Rutger, Beumer, Inès, Glas, Annuska M., Peeper, Daniel, Wesseling, Jelle, Simon, Iris M., Wessels, Lodewyk, Linn, Sabine C., Zwart, Wilbert
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2016
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5085127/
https://ncbi.nlm.nih.gov/pubmed/27129152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8983
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge